The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.

Launched by MAHIDOL UNIVERSITY · Mar 27, 2024

Keywords

ClinConnect Summary

The results of the health survey of the Thai population through physical examinations in the year 2022 found that among Thai people aged 18 and older, the prevalence of obesity (BMI ≥25 kg/m2) was 44.9% (40.3% in males and 49.2% in females), which has increased significantly over the past decades. This condition is a significant factor contributing to the rising incidence of nonalcoholic fatty liver disease (NAFLD) among the Thai population. NAFLD refers to fatty liver disease in individuals who consume alcohol in amounts less than 140 grams per week for females or less than 210 grams per w...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants must be diagnosed with MASLD according to the diagnostic criteria of the A multi-society Delphi consensus statement on new fatty liver disease nomenclature 2023, with evidence of hepatic steatosis and alcohol consumption of less than 140 grams per week for females or less than 210 grams per week for males, along with at least one of the clinical characteristics of metabolic syndrome.
• • 2. Participants must be at least 18 years old at the time of enrollment.
• • 3. Patients must consent to blood testing for the identification of the patatin like phospholipase domain containing-3 gene polymorphism.
• Exclusion Criteria:
• • 1. Individuals who engage in regular exercise for at least 20 minutes per day, at least 3 days per week.
• • 2. Individuals who have regular physical activity with walking exceeding 3000 steps per day before participating in the study.
• • 3. Individuals diagnosed with other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, Wilson's disease, liver cancer, hemochromatosis, liver cirrhosis, or others.
• • 4. Individuals diagnosed with diseases that may affect non-alcoholic fatty liver disease, such as HIV, various chronic inflammatory diseases, or connective tissue disorders.
• • 5. Individuals taking medications known to promote fatty liver disease, including amiodarone, steroids, methotrexate, hormonal medications, or immunosuppressants.
• • 6. Individuals who have previously taken medications known to impact fatty liver disease, including vitamin E, pioglitazone, Glucagon-like peptide-1 agonists, SGLT2 inhibitors.
• • 7. Participants intending to join weight loss programs or undergo bariatric surgery for obesity treatment.
• • 8. Individuals with cirrhosis.
• • 9. Individuals diagnosed with liver cancer.
• • 10. Individuals with severe chronic diseases still exhibiting symptoms during physical activity that may exacerbate the disease, such as coronary artery disease, chronic obstructive pulmonary disease, or severe osteoarthritis.
• • 11. Patients with contraindications for undergoing MRI examinations, such as claustrophobia or having body implants or materials that are incompatible with MRI scanning.
• • 12. Women who are pregnant.
• • 13. Individuals who do not provide formal consent to participate in the research project.